Kinoxis Therapeutics Pty Ltd

Kinoxis Therapeutics is a clinical-stage biotechnology company based in Australia, dedicated to developing novel therapeutics for social dysfunction and substance use disorders. Their approach focuses on restoring normal social functioning by rebalancing activity in malfunctioning social pathways in the brain, specifically targeting the oxytocin receptor. The company has developed a pipeline of promising therapeutic compounds, including their lead candidate KNX100, which is currently being explored for the mitigation of opioid withdrawal symptoms. Kinoxis has secured funding from a consortium of investors, including Uniseed, and has also received significant grants from the US National Institutes of Health.

Kinoxis is led by an experienced executive team with expertise in drug development, clinical research, and business development. They have built strategic partnerships with organizations like Boehringer Ingelheim to advance their research and clinical development programs. Kinoxis's work holds great potential to address the escalating demand for effective treatments for substance use disorders and social dysfunction, significantly improving the lives of those affected by these conditions.

Kinoxis Therapeutics is an Australian biotechnology company focused on developing novel treatments for social dysfunction and substance use disorders. They are creating innovative small molecule therapeutics that target specific pathways in the brain involved in social behavior, with a particular emphasis on the oxytocin receptor. Kinoxis believes their approach holds promise for breakthroughs in treating a range of disorders affecting the brain and mind, including autism spectrum disorder, social anxiety disorder, substance use disorders, schizophrenia, depression, and dementia.

Kinoxis Therapeutics fosters a collaborative and innovative culture, driven by a shared passion for developing groundbreaking treatments for social dysfunction and substance use disorders. The company values its multidisciplinary research team, comprised of seasoned experts and enthusiastic scientists, who work together to advance their pipeline of novel therapeutics. This dedication to scientific excellence is paired with a focus on building a strong and supportive environment that encourages collaboration and the exchange of ideas.